The Significance of KIT (CD117) in Gastrointestinal Stromal Tumors

Hirota S , Isozaki K , Moriyama Y , Hashimoto K , Nishida T , Ishiguro S , Kawano K , Hanada M , Kurata A , Takeda M , Muhammad Tunio G , Matsuzawa Y , Kanakura Y , Shinomura Y , Kitamura Y . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580 1998

Sarlomo-Rikala M , Kovatich AJ , Barusevicius A , Miettinen M . CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728-734 1998

Fletcher CDM , Berman JJ , Corless C , Gorstein F , Lasota J , Longley BJ , Miettinen M , O’Leary TJ , Remotti H , Rubin BP , Shmookler B , Sobin LH , Weiss SW . Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465 2002

Heinrich MC , Rubin BP , Longley BJ , Fletcher JA . Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484-495 2002

Rubin BP , Singer S , Tsao C , Duensing A , Lux ML , Ruiz R , Hibbard MK , Chen CJ , Xiao S , Tuveson DA , Demetri GD , Fletcher CD , Fletcher JA . KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121 2001

Lux ML , Rubin BP , Biase TL , Chen CJ , Maclure T , Demetri G , Xiao S , Singer S , Fletcher CD , Fletcher JA . KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791-795 2000

Druker BJ , Tamura S , Buchdunger E , Ohno S , Segal GM , Fanning S , Zimmermann J , Lydon NB . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566 1996

Druker BJ , Talpaz M , Resta DJ , Peng B , Buchdunger E , Ford JM , Lydon NB , Kantarjian H , Capdeville R , Ohno-Jones S , Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 2001

Heinrich MC , Griffith DJ , Druker BJ , Wait CL , Ott KA , Zigler AJ . Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932 2000

Tuveson DA , Willis NA , Jacks T , Griffin JD , Singer S , Fletcher CD , Fletcher JA , Demetri GD . STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20:5054-5058 2001

van Oosterom AT , Judson I , Verweij J , Stroobants S , Donato di Paola E , Dimitrijevic S , Martens M , Webb A , Sciot R , Van Glabbeke M , Silberman S , Nielsen OS . European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423 2001

Demetri GD , von Mehren M , Blanke CD , Van den Abbeele AD , Eisenberg B , Roberts PJ , Heinrich MC , Tuveson DA , Singer S , Janicek M , Fletcher JA , Silverman SG , Silberman SL , Capdeville R , Kiese B , Peng B , Dimitrijevic S , Druker BJ , Corless C , Fletcher CDM , Joensuu H . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480 2002

Miettinen M , Sobin LH , Sarlomo-Rikala M . Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with reference to CD117 (KIT). Mod Pathol 13:1134-1142 2000

Yantiss RK , Spiro IJ , Compton CC , Rosenberg AE . Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: A clinically important differential diagnosis. Am J Surg Pathol 24:947-957 2000

Hornick JL , Fletcher CDM . Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 117:188-193 2002

Lucas DR , al-Abbadi M , Tabaczka P , Hamre MR , Weaver DW , Mott MJ . c-Kit expression in desmoid fibromatosis: Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 119:339-345, 2003

Mace J , Sybil Biermann J , Sondak V , McGinn C , Hayes C , Thomas D , Baker L . Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373-2379 2002

Ma Y , Zeng S , Metcalfe DD , Akin C , Dimitrijevic S , Butterfield JH , McMahon G , Longley BJ . The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-1744 2002

Tian Q , Frierson HF Jr , Krystal GW , Moskaluk CA . Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154:1643-1647 1999

Heinrich MC , Corless CL , Duensing A , McGreevey L , Chen CJ , Joseph N , Singer S , Griffith DJ , Haley A , Town A , Demetri GD , Fletcher CD , Fletcher JA . PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003

Hirota S , Ohashi A , Nishida T , Isozaki K , Kinoshita K , Shinomura Y , Kitamura Y . Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125:660-667 2003

Heinrich MC , Corless CL , Demetri GD , Blanke CD , von Mehren M , Joensuu H , McGreevey LS , Chen C-J , Van den Abbeele AD , Druker BJ , Kiese B , Eisenberg B , Roberts PJ , Singer S , Fletcher CDM , Silberman S , Simitrijevic S , Fletcher JA . Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349 2003

Medeiros F , Corless C , Duensing A , Mornick JL , Oliveira AM , Heinrich MC , Fletcher JA , Fletcher CAM . KIT-negative gastrointestinal stromal tumors: Proof of concept and therapeutic implications. Am J Surg Pathol 2004, in press